About Cronos Group Inc. Cronos is an innovative global cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology and product development.
Cronos Group (NASDAQ:CRON) reported what executives described as a record year in 2025, with organic net revenue growth of 25 ...
Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025 ...
Hosted on MSN
Cronos signals revenue boost potential with 70% flower capacity increase amid international momentum
Earnings Call Insights: Cronos Group Inc. (CRON:CA) Q3 2025 Michael Gorenstein, President, CEO & Chairman, stated that "Cronos delivered another record quarter in Q3 2025, underscoring the continued ...
Cronos Group Inc. (NASDAQ:CRON) is one of the Low Risk Penny Stocks to Buy Now. On February 26, Cronos Group Inc. (NASDAQ:CRON) reported its fiscal Q4 2025 earnings. The company posted $44.53 million ...
Shares of Cronos Group Inc. CRON slipped 1.14% to $2.60 Tuesday, on what proved to be an all-around dismal trading session for the stock market, with the NASDAQ Composite Index COMP falling 1.02% to ...
Shares of Cronos Group Inc. CRON rose 1.60% to $2.54 Monday, on what proved to be an all-around positive trading session for the stock market, with the NASDAQ Composite Index COMP rising 1.22% to ...
Hosted on MSN
Cronos just bought Europe’s top cannabis producer — is this the catalyst investors have waited 5 years for?
For years, North American cannabis investors have endured a brutal hangover. Cronos Group (NASDAQ:CRON), once a darling of the 2018-2019 marijuana mania, watched its share price collapse more than 95% ...
TORONTO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cronos Group Inc. (CRON) (“Cronos” or the “Company”) will hold its 2025 third quarter earnings conference call on Thursday, November 6, 2025 at 8:30 a.m. ET.
Shares of Canada-based Cronos Group CRON rose 9% on Tuesday after the company announced plans to acquire CanAdelaar, a leading cannabis company in the Netherlands. Per the terms of the agreement, ...
The average one-year price target for Cronos Group (NasdaqGM:CRON) has been revised to $3.62 / share. This is an increase of 104.89% from the prior estimate of $1.77 dated June 20, 2025. The price ...
TORONTO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (CRON:CA) (“Cronos” or the “Company”), a leading global cannabinoid company, today announced the launch of its Lord Jones® premium cannabis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results